Marker Therapeutics Inc (MRKR)

[TomP1]

Yes: with data.

Our primary objective for the next several quarters is to continue enrolling patients into our three active Phase 2 trials as efficiently as possible, in order to reach many meaningful value inflection points for our shareholders. In parallel we expect to launch additional clinical studies for each of our novel cancer vaccine candidates later this year, to generate even more value for the company.